Ourself’s Clinical Data Published in Dermatologic Surgery

Skincare brand Ourself announced that clinical data evaluating its patented delivery technology, Tiered-Release Vesicles (TRVs), was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery.

The publication highlights that TRVs have the potential to “revolutionize” skincare by enabling the delivery of large, bioactive molecules directly into the epidermis and dermis. The Ourself delivery method promises to reshape the way we care for our skin and opens new possibilities for enhancing cosmetic outcomes topically, officials said.

“Publication of this data reinforces that Ourself is setting a new standard in topical delivery,” said Jim Hartman, Ourself’s CEO. “We are excited to lead these advancements and look forward to the growth and innovation this breakthrough will inspire for our brand and the industry as a whole.”

“Tiered-Release Vesicles represent a revolutionary advancement in dermal delivery technology, addressing a stagnation in the industry that has persisted for over four decades,” said Ashish C. Bhatia, MD, FAAD, author and board-certified dermatologist and Mohs surgeon at Oak Dermatology.

Changing the Paradigm

For decades, the skin’s outermost layer, the stratum corneum, has long been a barrier that limits the effectiveness of skincare products, blocking essential ingredients from reaching deeper layers. Traditional delivery systems like liposomes have failed to penetrate deeply enough to achieve substantial results—TRVs change this paradigm.

Amir Moradi, MD, MBA lead author and double board-certified facial plastic and otolaryngology-head and neck surgeon at Moradi MD, called the Tiered-Release Vesicle delivery system a “major step” forward for skincare.

“These developments redefine what is now achievable in topical delivery, unlocking limitless potential for the future of skincare,” she said.